Eli Lilly Shares Hit All-Time High on EU Panel Opinion, Medicare Expansion
Eli Lilly (LLY) shares hit an all-time high on Friday, driven by a positive EU panel opinion for Jaypirca and an expanded Medicare coverage for Zepbound and Foundayo at $50 per month.
Key Numbers
Shares of Eli Lilly (NYSE: LLY) reached an all-time high on Friday, buoyed by a positive opinion from a European Union panel for its cancer drug Jaypirca and an expansion of Medicare coverage for its weight-loss drugs Zepbound and Foundayo.
Details of the Move
The historic high followed a recommendation by an EU committee to approve Jaypirca (pirtobrutinib) for certain types of blood cancer. Simultaneously, the company announced an expanded Medicare program covering Zepbound and Foundayo at a price of $50 per month, increasing accessibility to these treatments.
Context
The news comes as Eli Lilly faces growing competition in the diabetes and obesity drug market from companies like Novo Nordisk. The potential EU approval of Jaypirca could open a new revenue stream in oncology.
What It Means for Investors
The developments highlight Eli Lilly's ability to diversify its pipeline and expand access to its drugs, potentially boosting long-term investor confidence. However, regulatory hurdles and competitive dynamics remain key factors to watch.
Frequently Asked Questions
Found this useful? Share it